Condition: Viral Infection · Primary Immune Deficiency Disorder · Sponsor: New York Medical College
BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).
This description comes directly from the study's public registry record.
Mitchell S Cairo, MD · 9145942150 · mitchell_cairo@nymc.edu
Lauren Harrison · 16172857844 · lauren_harrison@nymc.edu
Always discuss trial participation with your own doctor first.
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| New York Medical College | Vallhala, New York, United States | Recruiting |
| Nationwide Children's Hosptial | Columbus, Ohio, United States | Recruiting |
| Children's Hospital of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04197596